Aldeyra Therapeutics (ALDX) Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis
Go back to Aldeyra Therapeutics (ALDX) Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis| ALDEYRA THERAPEUT (NASDAQ: ALDX) | Delayed: 2.17 +0.12 (5.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.05 | 52 Week High | $8.19 | |||
| Open | $2.00 | 52 Week Low | $3.39 | |||
| Day High | $2.21 | P/E | N/A | |||
| Day Low | $2.00 | EPS | $0.00 | |||
| Volume | 1,022,180 | |||||
